GlassScriptPhysician profile
Samuel T Clark
NPI 1073506036
$1,635.74
in general payments reported to CMS, 2019-2025
25 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.80 · 2020: $107 · 2021: $48.37 · 2022: $397 · 2023: $464 · 2024: $226 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.22 | 2022-2025 | Ubrelvy, Qulipta, Linzess |
| Amgen INC. | $202.29 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $135.66 | 2022-2025 | |
| Abbott Laboratories | $87.78 | 2023-2025 | Proclaim, Freestyle Libre 3, Octrode |
| Novartis Pharmaceuticals Corporation | $61.49 | 2022-2023 | |
| Astellas Pharma US INC | $61.03 | 2023-2025 | Veozah |
| Novo Nordisk INC | $50.68 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $50.61 | 2023-2025 | Airsupra, Breztri |
| Radius Health, INC. | $48.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.08 | 2020-2023 | Jardiance |
| Esperion Therapeutics, INC. | $38.30 | 2020-2023 | Nexletol |
| Phathom Pharmaceuticals, INC. | $37.59 | 2023-2024 | Voquezna |
| Lilly USA, LLC | $37.41 | 2022 | |
| Axsome Therapeutics, INC. | $29.76 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $27.12 | 2024 | Trelegy Ellipta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $26.89 | 2019 | |
| Merck Sharp & Dohme LLC | $24.80 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $23.46 | 2025 | Gemtesa |
| Teleflex LLC | $21.97 | 2023 | Urolift |
| Tolmar, INC. | $20.06 | 2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $15.46 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $14.89 | 2020 | |
| Phadia US INC. | $14.85 | 2024 | Immunocap |
| Medtronic, INC. | $14.66 | 2023 | Micra |
| Allergan, INC. | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.